121911-71-5

Basic information

• Product Name: VX-770
• Synonyms: VX-770;5-Methyl-2-(5-phenyl-1H-pyrazol-3-yl)phenol;5-Methyl-2-(3-phenyl-1H-pyrazol-5-yl)phenol;Phenol, 5-methyl-2-(5-phenyl-1H-pyrazol-3-yl)-;5-Methyl-2-(5-phenyl-2H-pyrazol-3-yl)-phenol;UITPHBJALGIKSW-UHFFFAOYSA-N
• CAS NO: 121911-71-5
• Molecular Formula: C16H14N2O
• Molecular Weight: 250.30
• EINECS: -0
• Mol File: 121911-71-5.mol
• Article Data: 0

Chemical Properties

• Melting Point: 177℃
• Boiling Point: 481.243 °C at 760 mmHg
• Flash Point: 244.847 °C
• Appearance: /
• Density: 1.213
• CAS DataBase Reference: VX-770(CAS DataBase Reference)
• NIST Chemistry Reference: VX-770(121911-71-5)
• EPA Substance Registry System: VX-770(121911-71-5)

Safety Data

• Hazardous Substances Data: 121911-71-5(Hazardous Substances Data)

Usage

General Description

VX-770, also known as Ivacaftor, is a medication used to treat cystic fibrosis in individuals with specific genetic mutations. It works by targeting and increasing the activity of the defective protein responsible for regulating the movement of salt in and out of cells. By doing so, VX-770 helps improve lung function and reduce the symptoms associated with cystic fibrosis, such as difficulty breathing and frequent lung infections. The medication is taken orally and is generally well-tolerated, with common side effects including respiratory symptoms, nausea, and headache. Overall, VX-770 has been found to significantly improve the quality of life for individuals with cystic fibrosis and has been approved by regulatory agencies for use in certain patient populations.